Phase 2 Trial Seeking Patients for Zejula-Avastin Combo as Maintenance Therapy for Advanced Ovarian Cancer

Phase 2 Trial Seeking Patients for Zejula-Avastin Combo as Maintenance Therapy for Advanced Ovarian Cancer
Tesaro is recruiting for its Phase 2 trial testing its therapy Zejula (niraparib) plus Avastin (bevacizumab, Genentech) as a maintenance therapy for women with advanced ovarian cancer who achieved at least a partial response after platinum-based chemotherapy plus Avastin. The study — called OVARIO (NCT03326193) — is looking for 90 patients, regardless of their BRCA mutation or homologous recombination deficiency (HRD) status, with advanced (stage 3b and 4) epithelial ovarian, fallopian tube, or peritoneal cancer. Information on enrollment can be found here. The trial detail’s will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in the poster, “OVARIO: The phase 2, single-arm, open-label study of maintenance therapy with niraparib + bevacizumab in patients with advanced ovarian cancer following response on frontline platinum-based chemotherapy.” Trial participants are required to have achieved complete response (be cancer free), partial response, or no evidence of disease after the front-line platinum-based chemotherapy. Participants will receive a combination of Zejula and Avastin. Zejula will be given as a pill every day in 21-day cycles. Avastin will be administered intravenously on the first day of each cycle for up to 15 months. Patients w
Subscribe or to access all post and page content.